

The Syndrome of Irreversible Lithium-Effectuated Neurotoxicity: A Scoping Review

ABSTRACT

The Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT) is a rare but concerning neurological complication resulting from lithium intoxication. Despite being reported since the 1960s, SILENT remains poorly understood and previous reviews on this topic commonly have been narrative. We therefore conducted a scoping review to assess the nature and scope of the research literature on the long-term neurological sequelae of lithium toxicity and determine the current knowledge of SILENT. A comprehensive and systematic literature search, using the MEDLINE, Embase, and Web of Science databases (from inception to July 2023), was conducted for English and Dutch articles, assessing the long-term neurological sequelae of lithium intoxication. Key information concerning clinical manifestations, risk factors, therapeutic approaches, or preventive measurements was extracted. We reviewed 91 articles, extracting information from 117 cases of SILENT. The prevailing outcome observed was persistent cerebellar dysfunction (77% of cases), often in combination with other sequelae. Other common sequelae included cognitive problems, parkinsonism, choreoathetosis, tardive dyskinesia, and peripheral neuropathy. The most common (61.4%) acute neurological symptom in the development of SILENT is an altered level of consciousness ranging from confusion to comatose states. Cerebellar sequelae were mentioned in 77% of cases as most common persistent sequelae. Antipsychotic use was mentioned in 59% of cases and fever was reported in 37.6% of cases. Scientific knowledge about this phenomenon has not advanced much since its initial reports in the 1960s and 1970s. While the use of lithium has become much more stringent than it had been in years past, and the occurrence of SILENT is rather exceptional, raising awareness about SILENT nevertheless remains crucial to avoid deleterious neurological consequences. Comprehensive, high-quality research in a systematic and standardized manner is therefore urgently needed to better understand this phenomenon.




Keywords: Lithium, neurotoxicity, neurological sequelae, affective disorder

Introduction

Since the 1950s, lithium has been introduced as a therapeutic intervention for managing recurrent depressive episodes. Subsequently, it received approval and gained widespread recognition as the benchmark treatment for adult patients with bipolar disorder, as it has also been found efficacious in the acute and maintenance treatment of bipolar disorder since 1970. Last, extensive scientific research has demonstrated the efficacy of lithium as an augmenting agent in cases of antidepressant non-responsiveness or treatment-resistant major depression.¹⁻⁵

Lithium has a relatively narrow therapeutic index and needs careful dose titration with follow-up of clinical neuropsychiatric side effects, concomitant with monitoring of lithium serum levels. Lithium toxicity is a common clinical problem that can be acute, "acute on chronic", or chronic. Most of these symptoms are reversible by dose reduction, interruption, or treatment withdrawal.² Over the last 50 years, however, there have been occasional reports in the literature of permanent (irreversible) neurological damage following lithium treatment, even without toxic serum concentrations or after discontinuing treatment. This serious adverse event was first described by Verbov in 1965,⁶ after which several other case reports appeared



Koen Konieczny 
Johan Detraux 
Filip Bouckaert 

University Psychiatric Center KU Leuven,
Kortenberg, Belgium

Corresponding author:
Koen Konieczny
✉ koen.konieczny@asster.be

Received: December 6, 2023
Revision Requested: January 15, 2024
Last Revision Received: January 21, 2024
Accepted: January 26, 2024
Publication Date: April 24, 2024

Cite this article as: Konieczny K, Detraux J, Bouckaert F. The syndrome of irreversible lithium-effectuated neurotoxicity: A scoping review. *Alpha Psychiatry*. 2024;25(2):190-205.



Copyright@Author(s) - Available online at alpha-psychiatry.com.
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

in the 1970s. In 1984, Schou introduced the definition of this complication as “a long-lasting neurological sequelae for over two months after discontinuing lithium treatment”.⁷

Later Adityanjee⁸ coined the descriptive acronym SILENT (syndrome of irreversible lithium-effectuated neurotoxicity).⁸

Although there have been some reviews on this topic in the past, they were all narrative.^{7,9-11} Recently, Verdoux et al¹² published a systematic review but limited their research question to the role of fever in the occurrence of neurological sequelae following lithium intoxication.¹² We therefore conducted a scoping review to assess the nature and scope of the research literature on the long-term neurological sequelae of lithium intoxication and determine the present current knowledge of SILENT. More specifically, we wanted to explore (1) the clinical manifestations of SILENT; (2) risk factors for the development of SILENT; (3) therapeutic approaches and preventive measures; and (4) whether clinical knowledge on this syndrome increased over the last 20 years.

Material and Methods

This scoping review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses, extension for scoping reviews (PRISMA-ScR).¹³

Search Strategy

A comprehensive and systematic literature search, using the MEDLINE (via PubMed), Embase, and Web of Science databases (from inception to July 2023) was conducted for English and Dutch articles, assessing the long-term neurological sequelae of lithium intoxication, presenting data on the clinical manifestations, risk factors and/or therapeutic approaches, or preventive measurements. One of the authors (J.D.), an experienced biomedical information specialist, constructed effective search strings for the different databases. Duplicates were removed using EndNote X9 (J.D.). After removing duplicates, titles and abstracts were screened by K.K., using Rayyan QCRI. K.K. reviewed the full text of the selected articles and assessed their eligibility. Articles that were deemed potentially relevant according to the selection criteria were included. Any disagreements were solved by consensus or by decision of the other reviewers (J.D. and F.B.). K.K. also attempted to identify additional studies by using the reference list of potentially relevant reports and articles.

Selection Criteria

Inclusion Criteria: Articles were included if they met the following inclusion criteria: (1) English or Dutch published, peer-reviewed articles; (2) in- or outpatients of any age and psychiatric diagnosis

without pre-existing neurological disease; (3) patients who took lithium and suffered from persistent neurological sequelae for at least 2 months after the cessation of the medication; (4) All study designs were eligible for inclusion if they provided additional cases.

Exclusion Criteria: Articles published in languages other than English or Dutch, grey literature (such as posters, conference abstracts/papers, dissertations, and website articles), studies or case-reports including patients with a follow-up period shorter than 2 months after withdrawal of the medication (this also included cases where fatal outcomes occurred within 2 months of treatment discontinuation), or cases without specifying a time frame following lithium discontinuation, were excluded.

Data Extraction

Data was extracted and mapped descriptively by K.K., using a data extraction form. This form included the following information:

(1) author and publication year; (2) age and gender; (3) nature of the neurological sequelae observed; (4) acute neurologic signs; (5) precipitating factors; (6) lithium dose (mg/day); (7) lithium maximum plasma level (mM/L); (8) co-prescribed drugs (antipsychotics and other medications).

Results

Selection Process

The initial search across the 3 databases yielded a total of 2903 reports (see Figure 1 for the PRISMA-ScR flowchart). Of these, 1149 duplicate reports were removed. Overall, 142 articles studies were selected as potentially eligible, of which 61 original records met the inclusion criteria. Thirty articles^{6,14-42} were added by cross-reference, making a total of 91 articles. All included articles were case reports, except for 2 reviews,^{10,11} including a total of 117 SILENT cases.

General Study Characteristics

The highest number of case reports is concentrated in the 1980s, with only a relatively small number occurring in the last 20 years. (1960s: n = 1; 1970s: n = 18; 1980s: n = 38; 1990s: n = 25; 2000s: n = 16; 2010s: n = 10; 2020s n = 9). The majority of articles documented a solitary case (n = 77, 85%). Ten articles documented 2 cases (11%), 1 three cases (1%), 1 four cases (1%), and 1 six cases (1%). The highest number of cases documented in a single article was 7 (1%).

Although 5 cases did mention existing neurological disease, they were ultimately included in the final review because of their indeterminate character.⁴³⁻⁴⁷

Patient and Treatment Characteristics

Even though we identified a total of 117 cases, not all of them provided complete information on all specific parameters. Hence, the mean and standard deviation (SD) for each parameter are based on varying numbers of observations.

Gender: There were 56% (n=65) female patients and 44% (n=52) male patients [mean years: 48.1; SD: 13.85; range: 15-72, with 14 cases (12%) aged ≥65 ('geriatric')].

Doses and Serum Levels of Lithium Treatment: Reported serum levels (n = 106) ranged from 0.25 mM/L to 8 mM/L (mean: 2.37 mM/L; SD: 1.55 mM/L).

MAIN POINTS

- *The syndrome of irreversible lithium-effectuated neurotoxicity is underreported, often misinterpreted, and misdiagnosed.*
- *Case reports without an acute lithium intoxication are rare.*
- *The initial phase is characterized by an altered level of consciousness followed by a cerebellar syndrome.*
- *Further research is needed as knowledge about this syndrome has not advanced much since initial reports.*




Figure 1 . Preferred reporting items for systematic reviews and meta-analyses flow diagram.

Eighty one reports provided data on drug toxicity. Excluding overdose cases ($n=14$), dose levels at which toxicity occurred varied from 438 mg/day to 2800 mg/day (mean dose: 1194 mg/day, SD: 465 mg/day, median 1200 mg/day, interquartile range 900-1500). Employing the Extracorporeal Treatments In Poisoning (EXTRIP) classification,⁴⁸ the distribution of maximum lithium levels is as follows: (i) no toxicity <1.5 mM/L $n=34$ (32.1%); (ii) mild toxicity 1.5-2.5 mM/L $n=27$ (25.5%); (iii) moderate toxicity 2.5-3.5 mM/L $n=23$ (21.7%); (iv) severe toxicity >3.5 mM/L $n=22$ (20.8%).

Drug Combinations: There were 41 (35%) cases where no other (psychotropic nor non-psychotropic) medication use was mentioned.

In 59% ($n=69$) of the cases, antipsychotic use was mentioned, with 78.3% ($n=54$) being a first-generation antipsychotic (FGA) and 21.7% ($n=15$) a second-generation antipsychotic (SGA). In total, we documented 11 different FGA and 4 different SGA molecules. The most frequently reported co-prescribed FGA was haloperidol, followed by chlorpromazine. Among the SGA, olanzapine was the most frequently reported.

Other co-prescribed psychotropic medications included tricyclic antidepressants (TCAs) ($n=11$), selective serotonin reuptake inhibitors (SSRIs) ($n=4$), antiepileptics ($n=10$), and anticholinergics/antihistamines. The indication for antiepileptic drugs was not always specified. Given the type of psychiatric conditions presented, we suppose that these medications were used as mood stabilizers. Other non-psychotropic medications can be found in Table 1.

Associated Medical Factors: Fever was mentioned in 44 cases (37.6%), for which the etiology was not specified in 27 cases. Infection was mentioned in 14 cases (but 4 of them did not indicate whether fever was present). For 6 of these cases fever was associated with neuroleptic malignant syndrome (NMS) and in 1 case with heatstroke.

Other medical conditions mentioned were dehydration, anorexia, alcohol abuse/intoxication, surgery, and diabetes insipidus.

Clinical Manifestations of SILENT: There was considerable variability in the reporting of neurological symptoms or syndromes. The manner of description also differed between acute neurological signs and persistent sequelae. For the acute signs, descriptions often employed symptom-based terminology (e.g. ataxic gait), while for persistent

Table 1. Case Reports of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity in Published Peer Reviewed Literature

Author and Publication Year	Age/Gender	Nature of Persistent Sequelae	Acute Neurologic Signs	Precipitating Factors	Lithium Dose (mg/day)	Lithium Maximum Plasma Level (mM/L)	Co-Prescribed Drugs
Verbov et al, 1965 ⁶	51/F	Cerebellar	Comatose, spasticity, plantar reflex	Fever, anorexia	1000		Chlorpromazine
Von Hartitzsch et al, 1972 ⁴⁹	50/F	Cerebellar, choreoathetosis, plantar reflex	Lethargy, ataxia, seizures, stupor, hyperreflexia, plantar reflex, coma		1600	5.0	Chlorpromazine
Von Hartitzsch et al, 1972 ⁴⁹	53/F	Cerebellar, choreoathetosis, plantar reflex	Disorientation, ataxia, coarse tremor, seizure, stupor, hyperreflexia, plantar reflex		1600	2.3	
Juul-Jensen and Schou, 1973 ⁴²	38/F	Cerebellar	Bilateral nystagmus, spasticity, hyperreflexia, myoclonus, seizures	Overdose (intentional)	900	5.6	Phenytoin
Juul-Jensen and Schou, 1973 ⁴²	55/F	Cerebellar	Tremor, rigidity, impaired consciousness	Dehydration, surgery		2.9	
Cohen & Cohen, 1974 ⁴¹	34/F	Cerebellar, dementia, EPS	Confusion, tremor, cogwheel rigidity, stupor, involuntary movements, dysarthria, ataxia, vertical nystagmus	Fever	1800	1.81	Haloperidol
Cohen & Cohen, 1974 ⁴¹	40/F	Cerebellar, EPS, medullar	Somnolence, tremor, muscular rigidity, ataxia, vertical nystagmus, dysarthria	Fever	1500	1.48	Haloperidol
Cohen & Cohen, 1974 ⁴¹	63/F	Cerebellar, choreoathetosis, EPS	Impaired consciousness, tremor, cogwheel rigidity, ataxia	Fever	1165	1.58	Haloperidol
Cohen & Cohen, 1974 ⁴¹	63/F	Cerebellar, choreoathetosis, EPS	Tremor, dysarthria, mask face, postural tremor, lethargy, rigidity	Fever	1800	2.45	Haloperidol
Johnson, 1976 ⁵⁰	50/F	Cerebellar, bulbar, medullar	Ataxia, slurred speech, fluctuating consciousness			3.0	
Goldwater & Pollack, 1976 ⁴⁰	57/F	Cerebellar, cognitive deficits	Tremor, mask face, confusion, mouthing movements, clasp knife spasticity, cogwheel rigidity, hyperreflexia, plantar reflex, oculogyric crisis, ophthalmotonic attacks		438	4.8	Phenytoin
Hansen and Amdisen, 1978 ⁵¹	65/M	Dementia	Stupor	Dehydration	32 (mmol/day)	2.1	
Hansen and Amdisen, 1978 ⁵¹	63/F	Cerebellar, dementia	Stupor		24 (mmol/day)	3.15	
Lobo et al, 1978 ³⁹	29/F	Papilledema	Blurred vision, papilledema, nonspecific difficulties with eyes		1800	1.2	
Julien et al, 1979 ⁵²	62/F	Cerebellar			1000	2.69	
Newman and Saunders, 1979 ⁴³	47/M	Cerebellar, paraplegia	Ataxia, spastic paraplegia, mental deterioration, stupor	Multiple sclerosis (?)		2.3	

(Continued)

Table 1. Case Reports of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity in Published Peer Reviewed Literature (Continued)

Author and Publication Year	Age/Gender	Nature of Persistent Sequelae	Acute Neurologic Signs	Precipitating Factors	Lithium Dose (mg/day)	Lithium Maximum Plasma Level (mM/L)	Co-Prescribed Drugs		
							Antipsychotics	Other Drugs	Other Drugs
Newman and Saunders, 1979 ⁴³	42/F	Axonal neuropathy	Coma, flaccid paralysis, absent tendon reflexes and plantar responses, proximal muscle weakness			1.9			
Thomas, 1979 ³⁸	58/F	Dementia	EPS, TD, confusional state, disorientation				Haloperidol		
Warick, 1979 ³⁷	36/M	Cerebellar	Obtunded sensorium, coarse tremors, ataxic, lethargic, uncommunicative, incontinent, plantar reflex	Infection, dehydration, alcohol abuse	2700	7.6			Clorazepate, sulfamethoxazole
Sampath et al, 1980 ⁵³	22/M	Cerebellar (dysarthria)	Drowsy, confused, irritable, memory deficits, coarse tremor, dysarthria, moderate weakness and hypotonia in all limbs, mild ataxia and nystagmus, symmetric diminished reflexes		1050	1.0			None
Peiffer, 1981 ⁵⁴	61/F	Cerebellar, parkinsonism, slight dementia	Bursts of perspiration, kinetic restlessness, chewing movements, slurred speech, uncoordinated fiddling movements, non-responsive, hyperreflexia	Fever	1668	2.02	Perazine		
Baker et al, 1981 ³⁶	37/M	Cerebellar	Delirium, dysarthria, nystagmus	Fever (legionnaire disease = pneumonia)	2400	1.2	Haloperidol		Benztropine, diphenhydramine and secobarbital
Pringuey et al, 1981 ³⁵	54/M	Cerebellar		Dehydration	1500	3.8			Digitalis
Spring and Frankl, 1981 ³⁴	53/M	Cerebellar, EPS	Cogwheeling, stupor, parkinsonian gait	Fever	2400	1.5	Haloperidol		Benztropine, diphenhydramine
Uchigata et al, 1981 ³³	56/M	Cerebellar, peripheral neuropathy	Drowsiness, dysarthria, muscle twitching, unsteady gait, rigidity	Fever	1800	1.4	Chlorpromazine, levomepromazine		
Sellers et al, 1982 ⁵⁵	43/F	Cerebellar	Unconsciousness, rigidity, tremor, opisthotonos, ataxia, dysarthria, nystagmus		750	2.5	Chlorpromazine, thioridazine		
Pamphlett and Mackenzie, 1982 ³²	31/M	Cerebellar, peripheral neuropathy	Confusion, weakness, and tremulousness		1800	3.63			
Singh, 1982 ³¹	36/F	Cerebellar	Confusion, ataxia, dysarthria, coarse tremor		1200	0.25	Fluphenazine		
Donaldson and Cunningham, 1983 ¹⁰	53/F	Cerebellar	Impaired speech, parkinsonism	Fever	1000	3.9	Haloperidol		Benztropine

(Continued)

Table 1. Case Reports of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity in Published Peer Reviewed Literature (Continued)

Author and Publication Year	Age/Gender	Nature of Persistent Sequelae	Acute Neurologic Signs	Precipitating Factors	Lithium Dose (mg/day)	Lithium Maximum Plasma Level (mM/L)	Co-Prescribed Drugs
Donaldson and Cunningham, 1983 ¹⁰	63/F	Cerebellar	Disorientation, dysarthria, dysphagia, ataxia	Fever	1000	1.9	Haloperidol Propranolol Procyclidine, hydrochloride
Manor, 1983 ⁵⁶	28/F	Cerebellar, choreoathetosis				3.9	
Mann et al, 1983 ⁵⁷	39/M	Facial dyskinesia (TD), choreoathetosis	Cogwheel rigidity			1.07	Haloperidol
Sandyk and Hurwitz, 1983 ⁵⁸	42/F	Dementia, cerebellar, EPS, frontal lobe signs, choreoathetosis	Rigidity, tremors, seizures, dysarthria, ataxia	Subfebrile	750	1.21	Haloperidol
Sandyk and Hurwitz, 1983 ⁵⁸	44/M	Cerebellar, facial dyskinesia (TD)	Confusion, ataxia, coarse tremors, oculogyric crisis, dysarthria, myoclonus		750	1.24	Haloperidol
Lewis, 1983 ⁵⁹	58/M	Facial dyskinesia (TD)			1200	0.9	Diazepam, desipramine
Apte and Langston, 1983 ³⁰	38/M	Cerebellar, choreoathetosis, cognitive deficits	Impaired speech, coarse tremor, involuntary movements, masklike face, asterixis	Fever, dehydration	8100 (intentional overdose)	5.7	
Apte and Langston, 1983 ³⁰	50/F	Cerebellar, choreoathetosis	Impaired short term memory, ataxia	Infection, alcohol abuse	1200	2.8	Tetracycline
Zorumski and Bakris, 1983 ²⁹	58/F	Choreoathetosis	Ataxia, dysarthria, confusion, choreoathetosis		1200	1.2	
Green, 1984 ²⁸	38/F	Cerebellar	Stupor, dysarthria, confusion, corticospinal tract signs		1200	2.06	Thiothixene
Bejar, 1985 ⁶⁰	23/M	Cerebellar	Confusion, coarse tremors, agitation, nausea and emesis	Fever	12000 (intentional overdose)	8.0	
Izzo and Brody, 1985 ⁶¹	58/F	Cerebellar	Unresponsive, focal seizures, rigidity, nystagmus			2.5	Haloperidol Furosemide, propranolol
Lippmann et al, 1985 ²⁷	41/M	Cerebellar	Comatose, myasthenia like presentation		Polypharmacy intentional overdose	7.4	Amitriptyline, nortriptyline, doxepin, ethylalcohol
Malhotra et al, 1985 ²⁶	42/M	Cerebellar	Tachycardia, gait ataxia	Fever (infection)	1500	0.85	
Pheterson et al, 1986 ²⁵	38/F	Cerebellar, subcortical dementia	Semi comatose state	Fever (infection)		2.4	Amitriptyline
Andrade et al, 1987 ⁴⁴	20/F	Cerebellar (nystagmus)	Nystagmus, confusion, disorientation, cerebellar, EPS	Moderate mental retardation (?)	900	0.5	
Jacome, 1987 ⁶²	27/M	Cerebellar, plantar reflex	Obtundation, rigidity, seizures			1.5	Haloperidol Diazepam

(Continued)

Table 1. Case Reports of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity in Published Peer Reviewed Literature (Continued)

Author and Publication Year	Age/Gender	Nature of Persistent Sequelae	Acute Neurologic Signs	Precipitating Factors	Lithium Dose (mg/day)	Lithium Maximum Plasma Level (mM/L)	Co-Prescribed Drugs	
							Antipsychotics	Other Drugs
Nagaraja et al, 1987 ⁶³	35/M	Cerebellar, EPS, peripheral neuropathy	Confusion, ataxia, tremor		2100	1.1		Chlorpromazine
Nagaraja et al, 1987 ⁶³	32/F	Cerebellar, EPS	Coma	Dehydration, fever	2100	3.0		Chlorpromazine
Nagaraja et al, 1987 ⁶³	32/M	Cerebellar, EPS		Dehydration, fever	1350	0.9		
Nagaraja et al, 1987 ⁶³	33/F	Cerebellar, EPS	Confusion, ataxia	Fever	1650	0.4		Chlorpromazine
Nagaraja et al, 1987 ⁶³	41/M	Cerebellar	Dysarthria, ataxia		900	0.7		
Nagaraja et al, 1987 ⁶³	56/M	Cerebellar, EPS, peripheral neuropathy	Ataxia		1200	0.7		Chlorpromazine, haloperidol
Tesio et al, 1987 ⁶⁴	51/M	Cerebellar, choreoathetosis	Lethargy, ataxia, seizures, stupor, hyperreflexia	Alcohol intoxication	24000 (intentional overdose)	3.7		Chlorpromazine Lorazepam
Yoshimoto, 1987 ⁶⁵	56/M	Cerebellar	Drowsiness, dysarthria, tremor, rigidity, coma	Fever	1800			
Van Den Broek et al, 1988 ⁶⁶	72/F	Hypokinetic rigid syndrome with TD	Soporosis, episodic profuse transpiration, disorientation, hypertonia, rigidity, plantar reflex	Fever	1200	0.9		Haloperidol
Saxena and Mallikarjuna, 1988 ²⁴	21/M	Cognitive deficits	Dysarthria, tremors, drowsiness, memory impairment		15000 (intentional overdose)	2.7		
Adityanjee, 1989 ⁶⁷	51/F	Cerebellar	Slowed speech, coarse tremor, ataxia, dysarthria, dysdiadochokinesia, incoordination	Fever	800	1.7		Propranolol
Van Scheyen, 1990 ⁶⁸	68/F	Dementia	Reduced consciousness, agitation, EPS, choreoathetosis, disorientation, cerebellar		600	0.7		Haloperidol
Verdoux and Bourgeois, 1990 ⁶⁹	31/M	Cerebellar	Vertical nystagmus, dysphagia, ataxia, dysarthria, coarse tremor	Fever, alcohol abuse, NMS	750	0.89		Diazepam
Levine and Puchalski, 1990 ²³	38/M	Papilledema (left eye)	Monocular blindness, headache, nystagmus		1200	1		
Levine and Puchalski, 1990 ²³	40/F	Visual blurring	Headache, nausea, blurred vision, tinnitus, nystagmus, papilledema		900	0.9		Fluphenazine Desipramine
Johnston et al, 1991 ²²	69/F	Peripheral neuropathy	Unconsciousness, encephalopathy, peripheral neuropathy	Fever, dehydration	1000	1.89		

(Continued)

Table 1. Case Reports of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity in Published Peer Reviewed Literature (Continued)

Author and Publication Year	Age/Gender	Nature of Persistent Sequelae	Acute Neurologic Signs	Precipitating Factors	Lithium Dose (mg/day)	Lithium Maximum Plasma Level (mM/L)	Co-Prescribed Drugs	
							Antipsychotics	Other Drugs
Khanna and Sethi, 1993 ²⁰	15/M	Cerebellar, EPS	Masked faces, sialorrhea, cogwheel rigidity, dysarthria, ataxia, dysmetria, dysdiadochokinesia, intention tremor, dysphasia, paresis of tongue	Fever	750	0.4	Haloperidol	
Schneider and Mirra, 1994 ⁷¹	67/M	Cerebellar	Encephalopathy and coma, dysarthria, muscular weakness, tremor, ataxia, hyperreflexia		2100	4.04	Perphenazine	Carbamazepine, verapamil, quinapril, hydralazine
Swartz and Jones, 1994 ⁷²	54/F	Cognitive deficits	Jerking tremors, coma		1200	6.3	Fluphenazine	Aminophylline
Swartz and Jones, 1994 ⁷²	58/F	Brainstem lesion, cognitive deficits	Stupor, cogwheel rigidity	Dehydration, fever	1500	3.4	Trifluoperazine	Amitriptyline, alprazolam, L-thyroxine
Borggreve et al, 1995 ³	59/F	Cerebellar, cognitive deficits	Somnolence, incoherence, disorientation, dysarthria, generalized myoclonia		800	3.2		Carbamazepine
Mani et al, 1996 ⁷⁴	24/F	Cerebellar	Tremors, diarrhea, lethargy, rigid extensor posturing, vertical nystagmus		1000	0.8	Haloperidol, chlorpromazine	
Khan et al, 1997 ⁷⁵	63/M	Cerebellar, EPS, cognitive deficits, (CPM)	Lethargy, confused, bedridden, mute, brisk tendon reflexes, blepharospasm, positive glabellar reflex	Diabetes insipidus	300	1.5	Fluphenazine, amantadine	Triamterene/hydrochlorothiazide
Kores and Lader, 1997 ¹¹	60/M	Cerebellar	Confusion, myoclonic jerks, dysarthria, vomiting, sweating, truncal ataxia		1250	3.9		
Kores and Lader, 1997 ¹¹	61/F	Cerebellar	Confusion, disorientation, ataxia, agitation, dysarthria	Dehydration	800	2.2		Naproxen, paracetamol/dihydrocodeine
Kores and Lader, 1997 ¹¹	29/F	Cerebellar	Diarrhea, vomiting, incontinence, ataxia, dysarthria		1200	1.67		
Kores and Lader, 1997 ¹¹	71/F	Cerebellar	Arrhythmia, tremor, dysarthria, ataxia			2.63	Trifluoperazine	Diuretic, NSAID
Kores and Lader, 1997 ¹¹	64/F	Cerebellar, dementia	Diarrhea, muscle twitching, dementia, impairment of consciousness	NMS (fever not mentioned, but criterium of NMS)			Haloperidol	Diuretic, betablocker, diclofenac, coproxamol
Kores and Lader, 1997 ¹¹	45/F	Cerebellar, mild dementia	Confusion, ataxia	Dehydration		3.6		
Kores and Lader, 1997 ¹¹	42/F	Cerebellar, seizures	Agitation, seizures, spastic quadriplegia	Infection		2.18	Haloperidol	Erythromycin

(Continued)

Table 1. Case Reports of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity in Published Peer Reviewed Literature (Continued)

Author and Publication Year	Age/Gender	Nature of Persistent Sequelae	Acute Neurologic Signs	Precipitating Factors	Lithium Dose (mg/day)	Lithium Maximum Plasma Level (mM/L)	Co-Prescribed Drugs	
							Antipsychotics	Other Drugs
Meyer-Lindenberg and Krausnick, 1997 ⁶	72/F	Facial and abdominal dyskinesia (TD)	Ataxic gait, slurred speech, disorientation, blepharospasms, abdominal dyskinesia, chorea, intention tremor	Dehydration		1.1	No antipsychotics	
Epstein et al, 1997 ²¹	45/M	Cerebellar	Unconscious, seizures	Fever (heat stroke)	600		Haloperidol	Fluoxetine
Lal et al, 1997 ²⁰	50/F	Cerebellar	Altered sensorium, general rigidity	Fever, NMS			Haloperidol	Amitriptyline
Normann et al, 1998 ⁷	62/M	Choreoathetosis	Severe delirium, EPS		900	0.8	Haloperidol	Amitriptyline, valproate
Brumm et al, 1998 ⁷⁸	62/F	Dementia	Confusion, ataxia		Overdose (not specified)	3.9	Thiothixene	Benzotropine
Bischof et al, 1999 ⁹	49/M	Cerebellar	Cerebellar syndrome	Fever (pneumonia)		0.7	Trifluoperidol	Carbamazepine
Muthane et al, 2000 ⁴⁶	65/F	Parkinsonism, facial dyskinesia (TD)	Akathisia, parkinsonism	Peripheral diabetic neuropathy, fever	900	1.5		
Van der Steenstraten Achilles, 2001 ¹⁹	36/M	Cerebellar, cognitive deficits	Dysarthria, balance disorders, proximal muscle weakness, accommodation disorders	Fever (influenza)	1200	1.2	Pimozide	
Lang and Davis, 2002 ⁸⁰	44/M	Cerebellar, plantar reflex	Dysarthria, ataxia, leg weakness, dyspnea		1200	1.5	Trifluoperazine	Amitriptyline, aspirin, felodipine, verapamil
Fabisiak et al, 2002 ¹⁸	21/F	Blindness (due to CPM, persisted for 4 months)	Extreme thirst, vomiting, diarrhea, facial paresis, blindness, wide-based gait		1050			
Bartha et al, 2002 ¹⁷	51/M	Cognitive deficits	Psychomotor slowing, dysarthria, incoherence		1350	2.4		
Tuglu et al, 2005 ⁸¹	62/F	Perioral dyskinesia (TD)	Lethargy, disorientation, upward gaze palsy, bradykinesia, cogwheel rigidity, rest and postural tremor		900	3.0	Olanzapine	
Ozsoy et al, 2006 ⁸²	31/M	Cerebellar	Dysarthria, ataxia, dyskinesia, dysmetria, unable to walk or sit, intention tremor, bilateral horizontal nystagmus	Fever (pneumonia)	1200	0.9		Lamotrigine, escitalopram
Niethammer and Ford, 2007 ⁸³	52/F	Cerebellar	Confused, ataxia, dysarthria			3.5		
Niethammer and Ford, 2007 ⁸³	44/F	Cerebellar	Lethargy, nystagmus, ataxia	Fever (erythema multiforme)	1500	3.0	Perphenazine	Carbamazepine
Niethammer and Ford, 2007 ⁸³	57/M	Cerebellar	Rigidity with bilateral jerking movements	Fever	600	1.98	Quetiapine	Paroxetine, valproic acid, propranolol

(Continued)

Table 1. Case Reports of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity in Published Peer Reviewed Literature (Continued)

Author and Publication Year	Age/Gender	Nature of Persistent Sequelae	Acute Neurologic Signs	Precipitating Factors	Lithium Dose (mg/day)	Lithium Maximum Plasma Level (mM/L)	Co-Prescribed Drugs	
							Antipsychotics	Other Drugs
Tharoor et al, 2007 ⁸⁴	28/M	Cerebellar	Generalized rigidity	Fever, NIMS	800		Haloperidol, olanzapine	
De Cerqueria et al, 2008 ¹⁶	26/F	Cerebellar	Productive cough, vomiting, tremor, changes in gait, dysarthria, disorientation	Fever (pneumonia), dehydration	1500	1.9		
Keltner and Grant, 2008 ¹⁵	33/M	Severe neuropathy			2100 (accidental overdose)			
Fischera et al, 2009 ⁸⁵	45/M	Cerebellar	Ataxia, dysarthria dysphagia	Pneumonia, hepatitis C, hemophilia B	1072	1.0		
Ikeda et al, 2009 ⁸⁶	54/M	Cerebellar	Disorientation, tremor, dysarthria, hyperreflexia, coma	Fever	1200	3.45		
Porto et al, 2009 ⁸⁷	44/F	Cerebellar	Altered mental status, severe disattention, disorientation, tremor, dysarthria		6000 (intentional overdose)		Haloperidol, chlorpromazine	
Kohen, 2011 ⁸⁸	66/F	Cerebellar	Gait disturbance, confusion, dysarthria, ataxia, dysmetria, and dysphagia	Infection		2.0		
Van Landeghem en Vandenberghe, 2013 ⁴⁷	61/F	Cerebellar	Confusion, dysarthria, nystagmus, recurrent falls, urinary incontinence, dysmetria	Dehydration, sensory neuropathy, alcohol abuse in past	750	1.2		Disulfiram, sertraline, trazodone
Feldman et al, 2015 ⁸⁹	57/M	Cerebellar, EPS, brainstem dysfunction, cognitive impairment, perceptual disturbances	Altered mental status, perceptual disturbances, gait instability, tremors		900	2.6	Olanzapine	Tacrolimus, hydrochlorothiazide
Banwari et al, 2016 ⁹⁰	35/M	Cerebellar	Vomiting, coarse tremor, ataxia, restlessness, dysarthria, dysmetria, dysdiadochokinesia, nystagmus		2000 (accidental overdose)	4.42	Olanzapine	
Banwari et al, 2016 ⁹⁰	55/M	Cerebellar		Fever (upper respiratory tract infection)	900	2.52	Olanzapine	Clonazepam
Huang, 2016 ⁹¹	67/F	Cerebellar	Confusion, tremors, diarrhea	Fever	900	3.18	Quetiapine	
Cervello et al, 2017 ⁹²	31/M	Cerebellar, basal ganglia micro lesions	Altered consciousness, tremor, agitation, rigidity, nystagmus		12000 (intentional overdose)	7.4	Aripiprazole	
Rossi et al, 2017 ⁹³	33/M	Cerebellar		Fever (urinary tract infection)		1.18		
Medda et al, 2018 ⁹⁴	68/F	Cerebellar	Tremor, bradykinesia, rigidity, postural instability	Fever	900	2.68	Pimozide	Carbamazepine, nortriptyline, imipramine, hydrochlorothiazide

Table 1. Case Reports of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity in Published Peer Reviewed Literature (Continued)

Author and Publication Year	Age/Gender	Nature of Persistent Sequelae	Acute Neurologic Signs	Precipitating Factors	Lithium Dose (mg/day)	Lithium Maximum Plasma Level (mM/L)	Co-Prescribed Drugs	
							Antipsychotics	Other Drugs
Fountoulakis et al, 2019 ⁹⁵	68/F	TD			600	0.6		
Cuigniez et al, 2020 ⁹⁶	67/M	Cerebellar, TD, dementia	Confused, disorientation, agitation, word-finding difficulties, incoherence, coarse tremor		Accidental overdose	2.4	Quetiapine	Losartan, L-thyroxin, atorvastatin
Seña et al, 2020 ⁹⁷	56/M	Encephalopathic illness	Altered mental status, seizures		900	2.8	Risperidone	Clonazepam, biperiden
Laranjinha et al, 2021 ⁴⁵	54/F	Cerebellar	Slurred speech, agitation, seizures	Dehydration, mild mental retardation (?)	600	3.8		
Rhee and Kim, 2021 ⁹⁸	46/M	Cerebellar, EPS	Delirium	Fever, NMS	Intentional overdose	1.63	Aripiprazole	Lorazepam
Jha et al, 2021 ⁹⁹	50/M	Cerebellar	Dysarthria, past pointing, dysidiadochokinesis, wide-based gait		900		Risperidone	
Ocal et al, 2021 ¹⁴	59/F	Cerebellar, EPS	Speech impairment, lethargy, tremors, altered mental status	Fever, NMS	1200	2.16	Olanzapine	Levothyroxine
Akkus, 2022 ¹⁰⁰	67/F	TD	Orofacial dyskinesia		1200	0.92		
Fenner et al, 2022 ¹⁰¹	49/F	Dementia	Confusion, short term memory deficits, myoclonus, chorea, ataxia			3.3		
Farouji et al, 2023 ¹⁰²	61/M	Cerebellar, EPS	Confusion, disorientation, unsteady gait, agitation	Fever	Intentional overdose	>3.0	Quetiapine	Mirtazapine, gabapentin, doxepin, atorvastatin

CPM, central pontine myelinolysis; EPS, extrapyramidal symptoms; F, female; M, male; NMS, neuroleptic malignant syndrome; NSAID, nonsteroidal anti-inflammatory drug; TD, tardive dyskinesia.

sequelae, syndrome-based terminology was more common (e.g. cerebellar syndrome). Regarding acute signs, specificity regarding the nature of the symptoms was seldom provided; for instance, 'tremors' might encompass parkinsonian, cerebellar or other characteristics, but this distinction was not consistently specified. Consequently, we also recorded information in broad categorical terms.

The severity of the sequelae was not recorded, because there was also considerable variability in the reporting of this aspect. For example, for cerebellar sequelae, it ranged from moderate dysarthria to an advanced cerebellar syndrome rendering the patient dependent on assistance. Frequently, there was no further specification.

Acute Neurological Signs: The majority of cases (61.4%, $n=75$) were characterized by an altered level of consciousness, ranging from confusion to comatose states, followed by dysarthria and/or ataxic gait (53.8%, $n=63$) and 'tremors' (41.0%, $n=48$).

Other typical acute neurological signs included pyramidal signs (hyperreflexia and/or plantar reflex and/or spasticity and/or myoclonus) in 17.9% ($n=21$) of cases, bilateral nystagmus in 14.5% ($n=17$), and seizures occurring in 9.4% ($n=11$) of cases.

Persistent Sequelae: Cerebellar sequelae was mentioned in 77% ($n=90$) of the cases, in 46% of the cases ($n=41$) in combination with other sequelae. Cases without cerebellar sequelae accounted for 23% ($n=27$).

Other commonly occurring sequelae included cognitive problems/dementia (19.7%, $n=23$), parkinsonism/EPS (16.2%, $n=19$), choreo-athetosis (10.3%, $n=12$), tardive dyskinesia (8.5%, $n=10$), and peripheral neuropathy (6.0%, $n=7$). Most of these sequelae were present in combination, but some also occurred as standalone sequelae (see Table 1 for an overview of these sequelae).

Risk Factors: In 47% of cases ($n=55$), no precipitating factors were documented. In 41.9% of cases ($n=49$), fever or infection, either concurrent or not, was reported. Dehydration was noted in 12% of cases ($n=14$). Additionally, 4.3% of cases ($n=5$) exhibited concurrent or past alcohol misuse, and a similar percentage, 4.3% ($n=5$), experienced Neuroleptic Malignant Syndrome (NMS). The concomitant use of medications capable of elevating lithium levels, such as diuretics, NSAIDs, and certain antihypertensive drugs, was observed in 7.7% of cases ($n=9$).

Therapeutic Approaches: We did not document the therapeutic approach employed following the development of SILENT, as such descriptions were infrequent and even less comprehensive. Invariably, therapeutic approaches predominantly consisted of general rehabilitation, encompassing physical therapy, speech therapy, and occupational therapy.

Discussion

This study conducted an analysis of 91 articles focusing on lithium toxicity and its associated neurological sequelae. Our review indicated that the most common clinical manifestations during the initial acute presentation involved an altered level of consciousness, followed by cerebellar signs. Similarly, the most frequently reported persistent sequelae also exhibited cerebellar characteristics. Fever

and/or infection, followed by dehydration, were the most often reported risk factors. Applied therapeutic approaches were rarely mentioned and commonly involved a general rehabilitation of impaired functions.

Clinical Picture of SILENT

The onset of signs and symptoms related to lithium toxicity is gradual and insidious, which can lead to potential misinterpretation and misdiagnosis. Typically, it is only when the patient displays obvious and pronounced symptoms or when a clinical neurological examination reveals abnormalities that the possibility of lithium toxicity is taken into consideration.

The sequence of events often follows a rather typical pattern, resembling an acute organic brain syndrome (delirium), but frequently with gradually worsening symptoms, starting from early and relatively minor signs of intoxication to more severe manifestations. While this sequence of events is characteristic of acute lithium intoxication, a similar pattern is also observed, at least initially, in patients with long-lasting sequelae.

Cases of SILENT without an acute lithium poisoning phase are rare.¹² During the initial, acute toxic phase, various symptoms of an altered level of consciousness are commonly observed, such as altered mental state, confusion, disorientation, obtundation, lethargy, stupor or coma. Besides these symptoms, an acute cerebellar syndrome with symptoms such as wide-based ataxic gait, dysarthria, dysmetria, dysdiadochokinesia, hypotonia, nystagmus and (intention) tremor is also commonly observed in most cases.^{9,103}

As the presentation of SILENT in most cases typically starts with an acute intoxication (acute or "acute on chronic"), in the initial phase, no conclusion can be drawn regarding the development of SILENT. In the meantime, one should promptly and effectively mitigate the toxicity as much as possible.^{9,103}

Historically, cerebellar sequelae has been the most commonly neurological sequelae associated with SILENT, and we found a similar predominance in our study.

Risk Factors for Development of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity

Risk factors for developing an acute, "acute on chronic" or chronic lithium intoxication are well-known such as older age, reduced kidney function, dehydration, and concomitant use of diuretics.^{2,104} Some of these factors were mentioned in the included cases like dehydration, concomitant use of diuretics or antihypertensive medications and fever/infection.

Individuals who use lithium long-term face an elevated risk for developing lithium-induced nephrogenic diabetes insipidus. This condition results in a loss of renal urine-concentrating ability, leading to an increased susceptibility to lithium intoxication.¹⁰⁴

According to a recent systematic review, the connection between fever/infection and the development of cerebellar sequelae was observed primarily in cases with lithium plasma levels <2.5 mM/L independently from other characteristics. Furthermore, after adjusting for other variables, no correlation was observed between exposure to antipsychotics and the occurrence of cerebellar sequelae.¹² Nonetheless, one should be prudent to generalize the findings from

this review, as more large-scale studies are necessary to make firm conclusions.

It seems unlikely that the mechanism behind the temperature increase (fever or hyperthermia) plays a role, as the causal link between temperature elevation and cerebellar sequelae in lithium users is supported by the well-known sensitivity of the cerebellar cortex to temperature changes.^{11,93}

Although lithium currently is mainly used in the treatment of bipolar disorder and (treatment-resistant) major depression,^{4,105,106} it has been suggested that patients with schizoaffective disorder and marked psychotic symptoms may be more susceptible to lithium toxicity than most bipolar patients.^{10,107}

Elderly patients also have a higher risk for lithium intoxication. It is estimated that approximately 25% of all patients with bipolar disorder are elderly,¹⁰⁸ who are deemed more vulnerable for various reasons. Recent and relatively preliminary research indicated that higher age is associated with an increased level of neurological soft signs (NSS), which are subtle neurological abnormalities comprising deficits in sensory integration, motor coordination, and sequencing of complex motor acts. Moreover, bipolar disorder type I is associated with a higher degree of NSS compared to bipolar disorder type II. Furthermore, schizophrenia is linked to a greater extent of NSS than bipolar disorder.^{109–111} It therefore could be hypothesized that elderly patients with one of these diagnoses might be even more susceptible to the potential (long-term) toxic effects of lithium.

Kidney function naturally decreases with age as part of the normal aging process. Generally, elderly patients also have a higher prevalence of comorbidities, such as cardiovascular diseases, impaired kidney function, and cognitive issues. Moreover, long-term lithium treatment is associated with an increased decline in GFR (glomerular filtration rate) and a doubled risk of developing chronic kidney failure.^{112,113} As a logical consequence, older adults are at a higher risk of experiencing the adverse effects of lithium, including the development of (neuro)toxicity.¹¹⁴ Therefore, lower lithium levels, that have been proven to be effective, are pursued.^{106,115}

Higher lithium levels confer a higher risk of lithium toxicity. Even at lithium levels within normal limits, toxicity can occur. From clinical experience, we know that some people already develop toxic symptoms at lower levels, while others still do not show toxic symptoms at high levels.

The contributing factors are unknown. This requires high-quality and comprehensive research on this topic in a systematic and standardized way to better understand this phenomenon.

In none of the reports or reviews, we could find information on whether experiencing previous lithium intoxications makes individuals more susceptible to develop SILENT later in life if lithium therapy is continued.

Therapeutic Strategies

We presume that SILENT is frequently overlooked or attributed to other factors, especially in a population with chronic psychiatric conditions and defective features. It appears to encompass a spectrum of potential complications, with cerebellar sequelae being the most characteristic. Nonetheless, it is an extremely deleterious

iatrogenic complication. The unpredictable nature of lithium neurotoxicity underscores the importance of vigilant patient monitoring and education. If symptoms of lithium intoxication arise, even with serum concentrations within the therapeutic range, it is crucial to reduce or discontinue lithium treatment until the symptoms subside. In some cases of elevated lithium levels, haemodialysis is started, though further refinement of the current EXTRIP criteria is necessary to offer more precise guidance on which lithium-intoxicated patients are likely to benefit from haemodialysis.¹¹⁶ In fact, in clinical practice other levels of what is considered as toxic are used.¹¹⁷ Moreover, there is currently insufficient evidence to suggest that this intervention can prevent the development of neurological damage.¹¹⁸

Once irreversible damage occurs, significant treatment challenges arise. While some patients recover spontaneously, even after two months, the extent of recovery varies. In certain cases, the sequelae persist despite the passage of time. The neurological sequelae should be treated according to available options. Physiotherapy focusing on enhancing balance reactions, trunk stability, and coordination, logopedic training for speech rehabilitation and addressing dysphagia-related concerns, and occupational therapy, to enhance overall self-sufficiency are utilized.^{61,70}

A brief clinical neurological examination (including mental status, cranial nerves, motor and sensory assessment, coordination, reflexes and gait) to rule out subclinical signs of toxicity should undoubtedly be part of standard practice. Whether the implementation of NSS and cerebellar soft signs assessment in clinical practice provides added value will need to be determined through longitudinal studies that evaluate the associations between the severity of the pathology, psychosocial functioning, clinical outcomes, and structural and functional brain changes.¹¹⁰

Pathophysiology of Lithium-Induced Neurological Sequelae

Some neuropathological reports suggest that lithium may affect calcium homeostasis within Purkinje cells, leading to their selective impairment.^{16,54,83} Adityanjee et al⁹ proposed the hypothesis that lithium could induce demyelination in various brain regions, including the cerebellum. It has been reported that hyperthermia/fever can also cause cerebellar atrophy.^{19,93} As described above, fever is linked with the development of cerebellar sequelae.¹²

Nevertheless, the exact mechanism behind lithium-induced neurological sequelae, with a seemingly propensity for selective cerebellar damage, remains unclear, and it is possible that it is not solely attributed to lithium-induced neurotoxicity. For instance, it could be linked to significant osmotic fluctuations caused by volume depletion and dehydration resulting from nephrogenic diabetes insipidus, which might be more prevalent among elderly individuals, chronic lithium users, and those with impaired kidney function.¹¹⁶

The Concept of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity

In accordance with other reviews^{9–12} we used the definition of SILENT as introduced by Schou⁷: “prolonged neurological sequelae lasting for a minimum duration of two months after the discontinuation of lithium”. Nevertheless, the validity of this definition remains a subject of debate. Tesio,¹¹⁹ for example, proposed that the diagnosis of SILENT should involve the presence of persistent cerebellar signs for at least six months after the occurrence of lithium poisoning and

discontinuation of lithium treatment. Khanna⁷⁰ observed that significant continuous improvement can occur within the first 6 months, resulting in nearly complete recovery by the end of 9 months. In an effort to avoid therapeutic nihilism, it was therefore suggested by Khanna that the condition should be considered irreversible only if no substantial (less than 50%) recovery takes place in the initial 6 months. However, this proposal was not further explored or adopted. Taken all together, the concept of SILENT remains somewhat unclear.

As compared to previous reviews, the results of this scoping review did not reveal new findings about the syndrome, we can conclude that the scientific knowledge about this phenomenon has not advanced much since its initial reports. It is striking that, apart from available case reports and a few reviews, no dedicated research has been carried out to better understand this phenomenon. We also presume that there is significant underreporting of this syndrome due to a lack of recognition of cases that could potentially be diagnosed as SILENT. Although the use of lithium has become much more stringent than it has been in past years, and the occurrence of SILENT is rather exceptional, raising awareness about SILENT nevertheless remains crucial to avoid deleterious neurological consequences. This requires, in the first instance, a precise clinical description of the syndrome. Moreover, conducting high-quality and comprehensive research on this topic in a systematic and standardized way is also needed to better understand this phenomenon.

Limitations

Despite a comprehensive and systematic search of the literature, it is still possible that some relevant articles may have been missed as we excluded grey literature. We also excluded articles written in other languages than Dutch or English. Despite this, we believe that it is unlikely that these reports would have influenced the results significantly, due to the limited amount of cases they would add. Furthermore, there were great variations in the quality and depth of information provided in the included articles. The heterogeneity of reporting in case reports can pose challenges when attempting to synthesize the data.

Data Availability Statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – K.K., F.B.; Design – K.K., F.B., J.D.; Supervision – F.B., J.D.; Resources – K.K., F.B., J.D.; Materials – K.K., F.B., J.D.; Data Collection and/or Processing – K.K., J.D.; Analysis and/or Interpretation – K.K., F.B.; Literature Search – K.K.; Writing – K.K., F.B., J.D.; Critical Review – K.K., F.B., J.D.

Declaration of Interests: The authors have no conflicts of interest to declare.

Funding: The authors declare that this study received no financial support.

References

- Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. *BMJ*. 2013;346:f3646. [CrossRef]
- Hausmann R, Bauer M, Von Bonin S, Grof P, Lewitzka U. Treatment of lithium intoxication: facing the need for evidence. *Int J Bipolar Disord*. 2015;3(1):23. [CrossRef]
- Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. *Int J Bipolar Disord*. 2014;2(1):15. [CrossRef]
- Undurraga J, Sim K, Tondo L, et al. Lithium treatment for unipolar major depressive disorder: systematic review. *J Psychopharmacol*. 2019;33(2):167-176. [CrossRef]
- Abou-Saleh MT, Müller-Oerlinghausen B, Coppen AJ. Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression. *Int J Bipolar Disord*. 2017;5(1):11. [CrossRef]
- Verbov JL, Phillips JD, Fife DG. A case of lithium intoxication. *Postgrad Med J*. 1965;41(474):190-192. [CrossRef]
- Schou M. Long-lasting neurological sequelae after lithium intoxication. *Acta Psychiatr Scand*. 1984;70(6):594-602. [CrossRef]
- Adityanjee. The syndrome of irreversible lithium effectuated neurotoxicity. *J Neurol Neurosurg Psychiatry*. 1987;50(9):1246-1247. [CrossRef]
- Adityanjee MKR, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. *Clin Neuropharmacol*. 2005;28(1):38-49. [CrossRef]
- Donaldson IM, Cuningham J. Persisting neurologic sequelae of lithium carbonate therapy. *Arch Neurol*. 1983;40(12):747-751. [CrossRef]
- Kores B, Lader MH. Irreversible lithium neurotoxicity: an overview. *Clin Neuropharmacol*. 1997;20(4):283-299. [CrossRef]
- Verdoux H, Debruyne AL, Queuille E, De Leon J. A reappraisal of the role of fever in the occurrence of neurological sequelae following lithium intoxication: a systematic review. *Expert Opin Drug Saf*. 2021;20(7):827-838. [CrossRef]
- Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med*. 2018;169(7):467-473. [CrossRef]
- Öcal S, Simsek M, Irem Yildiz M. Lithium toxicity and neuroleptic malignant syndrome in a patient with bipolar disorder. *Austin Crit Care Case Rep*. 2021;5(4):1034.
- Keltner NL, Grant JS. Biological perspectives irreversible lithium-induced neuropathy: two cases. *Perspect Psychiatr Care*. 2008;44(4):290-293. [CrossRef]
- Cerqueira AC, Reis MC, Novis FD, et al. Cerebellar degeneration secondary to acute lithium carbonate intoxication. *Arq Neuro Psiquiatr*. 2008;66(3A):578-580. [CrossRef]
- Bartha L, Marksteiner J, Bauer G, Benke T. Persistent cognitive deficits associated with lithium intoxication: a neuropsychological case description. *Cortex*. 2002;38(5):743-752. [CrossRef]
- Fabisiak DB, Murray GB, Stern TA. Central pontine myelinolysis manifested by temporary blindness: a possible complication of lithium toxicity. *Ann Clin Psychiatry*. 2002;14(4):247-251. [CrossRef]
- Van der Steenstraten IM, Achilles RA. Permanent cerebellar sequelae after intoxication at therapeutic lithium levels: a case report. *Tijdschr Psychiatr*. 2001;43:271-275.
- Lal V, Sardana V, Thussu A, Sawhney IM, Prabhakar S. Cerebellar degeneration following neuroleptic malignant syndrome. *Postgrad Med J*. 1997;73(865):735-736. [CrossRef]
- Epstein Y, Albukrek D, Kalmovitch B, Moran DS, Shapiro Y. Heat intolerance induced by antidepressants. *Ann N Y Acad Sci*. 1997;813:553-558. [CrossRef]
- Johnston SR, Burn D, Brooks DJ. Peripheral neuropathy associated with lithium toxicity. *J Neurol Neurosurg Psychiatry*. 1991;54(11):1019-1020. [CrossRef]
- Levine SH, Puchalski C. Pseudotumor cerebri associated with lithium therapy in two patients. *J Clin Psychiatry*. 1990;51(6):251-253.
- Saxena S, Mallikarjuna P. Severe memory impairment with acute overdose lithium toxicity: a case report. *Br J Psychiatry*. 1988;152:853-854. [CrossRef]
- Pheterson AD, Miller L, Fox CF, Estroff TW, Sweeney DR. Multifocal neurological impairment caused by infection-induced rise in blood lithium and amitriptyline. *Int J Psychiatry Med*. 1986;16(3):257-262. [CrossRef]

26. Malhotra S, Sharma S, Awasthi A, Sharma BK. Cerebellar damage in a patient on lithium developing enteric fever : a case report. *Indian J Psychiatry*. 1985;27(3):255-258.
27. Lippmann S, Arnold D, Taylor J, Manshadi M. Lithium carbonate toxicity-induced cerebellar injury. *Arch Neurol*. 1985;42(6):515. [\[CrossRef\]](#)
28. Green JB. Permanent neurological deficits resulting from lithium toxicity. *Ann Neurol*. 1984;15(1):111. [\[CrossRef\]](#)
29. Zorumski CF, Bakris GL. Choreoathetosis associated with lithium: case report and literature review. *Am J Psychiatry*. 1983;140(12):1621-1622. [\[CrossRef\]](#)
30. Apte SN, Langston JW. Permanent neurological deficits due to lithium toxicity. *Ann Neurol*. 1983;13(4):453-455. [\[CrossRef\]](#)
31. Singh SV. Lithium carbonate/fluphenazine decanoate producing irreversible brain damage. *Lancet*. 1982;2(8292):278. [\[CrossRef\]](#)
32. Pamphlett RS, Mackenzie RA. Severe peripheral neuropathy due to lithium intoxication. *J Neurol Neurosurg Psychiatry*. 1982;45(7):656. [\[CrossRef\]](#)
33. Uchigata M, Tanabe H, Hasue I, Kurihara M. Peripheral neuropathy due to lithium intoxication. *Ann Neurol*. 1981;9(4):414. [\[CrossRef\]](#)
34. Spring G, Frankel M. New data on lithium and haloperidol incompatibility. *Am J Psychiatry*. 1981;138(6):818-821. [\[CrossRef\]](#)
35. Pringuey D, Yzombard G, Charbit JJ, et al. Lithium kinetics during hemodialysis in a patient with lithium poisoning. *Am J Psychiatry*. 1981;138(2):249-251. [\[CrossRef\]](#)
36. Baker PC, Price TR, Allen CD. Brain stem and cerebellar dysfunction with Legionnaires' disease. *J Neurol Neurosurg Psychiatry*. 1981;44(11):1054-1056. [\[CrossRef\]](#)
37. Warick LH. Lithium poisoning. Report of a case with neurologic, cardiac and hepatic sequelae. *West J Med*. 1979;130(3):259-263.
38. Thomas CJ. Brain damage with lithium/haloperidol. *Br J Psychiatry*. 1979;134:552. [\[CrossRef\]](#)
39. Lobo A, Pilek E, Stokes PE. Papilledema following therapeutic dosages of lithium carbonate. *J Nerv Ment Dis*. 1978;166(7):526-529. [\[CrossRef\]](#)
40. Goldwater L, Pollack M. Neurological sequelae after lithium intoxication. *N Z Med J*. 1976;84(575):356-358.
41. Cohen WJ, Cohen NH. Lithium carbonate, haloperidol, and irreversible brain damage. *JAMA*. 1974;230(9):1283-1287. [\[CrossRef\]](#)
42. Juul-Jensen P, Schou M. Permanent brain damage after lithium intoxication. *Br Med J*. 1973;4(5893):673. [\[CrossRef\]](#)
43. Newman PK, Saunders M. Lithium neurotoxicity. *Postgrad Med J*. 1979;55(648):701-703. [\[CrossRef\]](#)
44. Andrade C, Gangadhar BN, Channabasavanna SM. Pathological neurotoxicity with lithium. *Indian J Psychiatry*. 1987;29(3):279-281.
45. Laranjinha I, Dias R, Ferreira IH, Botelho L, Maia L, Faria R. Levodopa for syndrome of irreversible lithium-effectuated neurotoxicity: a SILENT recovery. *Sinapse*. 2021;21(2):97-99. [\[CrossRef\]](#)
46. Muthane UB, Prasad BNK, Vasanth A, Satishchandra P. Tardive Parkinsonism, orofacial dyskinesia and akathisia following brief exposure to lithium carbonate. *J Neurol Sci*. 2000;176(1):78-79. [\[CrossRef\]](#)
47. Van Landeghem K, Vandenbergh J. Irreversible neurological impairment despite normal serum lithium levels. *Tijdschr Geneesk*. 2013;69(12):593-597. [\[CrossRef\]](#)
48. Decker BS, Goldfarb DS, Dargan PI, et al. Extracorporeal treatment for lithium poisoning: systematic review and recommendations from the EXTRIP workgroup. *Clin J Am Soc Nephrol*. 2015;10(5):875-887. [\[CrossRef\]](#)
49. Von Hartitzsch B, Hoenich NA, Leigh RJ, et al. Permanent neurological sequelae despite haemodialysis for lithium intoxication. *BMJ*. 1972;4(5843):757-759. [\[CrossRef\]](#)
50. Johnson GFS. Lithium neurotoxicity. *Aust N Z J Psychiatry*. 1976;10(1):33-38. [\[CrossRef\]](#)
51. Hansen HE, Amdisen A. Lithium intoxication (Report of 23 cases and review of 100 cases from the literature). *Q J Med*. 1978;47(186):123-144. Available at: <https://www.embase.com/search/results?subaction=viewrecord&id=L8378501&from=export>.
52. Julien J, Vallat JM, Laguery A, Vital C. Myopathy and cerebellar syndrome during acute poisoning with lithium carbonate. *Muscle Nerve*. 1979;2(3):240.
53. Sampath G, Kumar YV, Narayanan HS, Rama Rao BS. Lithium neurotoxicity at "therapeutic" levels: a case report. *Indian J Psychiatry*. 1980;22(3):304-306.
54. Peiffer J. Clinical and neuropathological aspects of long-term damage to the central nervous system after lithium medication. *Arch Psychiatr Nervenkr (1970)*. 1981;231(1):41-60. [\[CrossRef\]](#)
55. Sellers J, Tyrer P, Whiteley A, Banks DC, Barer DH. Neurotoxic effects of lithium with delayed rise in serum lithium levels. *Br J Psychiatry*. 1982;140(6):623-625. [\[CrossRef\]](#)
56. Manor E. A case of reversible tachy-bradycardia syndrome and permanent neurological sequelae in lithium intoxication. *Arch Toxicol*. 1983;53:384-385. [\[CrossRef\]](#)
57. Mann S. Early onset of severe dyskinesia following lithium-haloperidol treatment. *Am J Psychiatry*. 1983;140(10):1385b. [\[CrossRef\]](#)
58. Sandyk R, Hurwitz MD. Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol: a report of 2 cases. *S Afr Med J*. 1983;64(22):875-876.
59. Lewis DA. Unrecognized chronic lithium neurotoxic reactions. *JAMA*. 1983;250(15):2029-2030. [\[CrossRef\]](#)
60. Bejar JM. Cerebellar degeneration due to acute lithium toxicity. *Clin Neuropharmacol*. 1985;8(4):379-381. [\[CrossRef\]](#)
61. Izzo KL, Brody R. Rehabilitation in lithium toxicity: case report. *Arch Phys Med Rehabil*. 1985;66(11):779-782.
62. Jacome DE. Cerebellar syndrome in lithium poisoning. *J Neurol Neurosurg Psychiatry*. 1987;50(12):1722. [\[CrossRef\]](#)
63. Nagaraja D, Taly AB, Sahu RN, Channabasavanna SM, Narayanan HS. Permanent neurological sequelae due to lithium toxicity. *Clin Neurol Neurosurg*. 1987;89(1):31-34. [\[CrossRef\]](#)
64. Tesio L, Porta GL, Messa E. Cerebellar syndrome in lithium poisoning: a case of partial recovery. *J Neurol Neurosurg Psychiatry*. 1987;50(2):235-235. [\[CrossRef\]](#)
65. Yoshimoto Y. A case of lithium intoxication with downbeat vertical nystagmus. *Auris Nasus Larynx*. 1987;14(2):71-75. [\[CrossRef\]](#)
66. van den Broek WW, van Hulst AM, Klompenhouwer JL, Moleman P. Lasting neurological damage with therapeutic plasma lithium levels. *Ned Tijdschr Geneesk*. 1988;132(45):2063-2066.
67. Adityanjee. The Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT). *Pharmacopsychiatry*. 1989;22(2):81-83. [\[CrossRef\]](#)
68. van Scheyen JD. Recovery from lithium neurotoxicity: a case study. *Acta Neuropsychiatr*. 1990;2(2):26-29. [\[CrossRef\]](#)
69. Verdoux H, Bourgeois ML. A case of lithium neurotoxicity with irreversible cerebellar syndrome. *J Nerv Ment Dis*. 1990;178(12):761-762. [\[CrossRef\]](#)
70. Khanna R, Sethi SS. Long - lasting lithium neurotoxicity in an adolescent. *Indian J Psychiatry*. 1993;35(2):135-136.
71. Schneider JA, Mirra SS. Neuropathologic correlates of persistent neurologic deficit in lithium intoxication. *Ann Neurol*. 1994;36(6):928-931. [\[CrossRef\]](#)
72. Swartz CM, Jones P. Hyperlithemia correction and persistent delirium. *J Clin Pharmacol*. 1994;34(8):865-870. [\[CrossRef\]](#)
73. Borggreve F, Collumbien ECA, Marien P, de Deyn PP. Lithium and neurotoxicity. *Tijdschr Geneesk*. 1995;51(22):1549-1554.
74. Mani J, Tandell SV, Shah PU, Karnad DR. Prolonged neurological sequelae after combination treatment with lithium and antipsychotic drugs. *J Neurol Neurosurg Psychiatry*. 1996;60(3):350-351. [\[CrossRef\]](#)
75. Khan AU, Chang FL, Howsepian A. Central pontine myelinolysis related to lithium toxicity. *Gen Hosp Psychiatry*. 1997;19(2):150-152. [\[CrossRef\]](#)
76. Meyer-Lindenberg A, Krausnick B. Tardive dyskinesia in a neuroleptic-naive patient with bipolar-I disorder: persistent exacerbation after lithium intoxication. *Mov Disord*. 1997;12(6):1108-1109. [\[CrossRef\]](#)
77. Normann C, Brandt C, Berger M, Walden J. Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction. *Pharmacopsychiatry*. 1998;31(5):201-204. [\[CrossRef\]](#)

78. Brumm VL, van Gorp WG, Wirshing W. Chronic Neuropsychological sequelae in a case of severe lithium intoxication. *Neuropsychiatry Neuropsychol Behav Neurol*. 1998;11(4):245-249.
79. Bischof F, Melms A, Fetter M. Persistent cerebellar deterioration in a patient with lobar pneumonia under lithium, carbamazepine, and trifluoperidol treatment. *Eur Psychiatry*. 1999;14(3):175-176. [CrossRef]
80. Lang EJ, Davis SM. Lithium neurotoxicity: the development of irreversible neurological impairment despite standard monitoring of serum lithium levels. *J Clin Neurosci*. 2002;9(3):308-309. [CrossRef]
81. Tuglu C, Erdogan E, Abay E. Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report. *J Korean Med Sci*. 2005;20(4):691-694. [CrossRef]
82. Ozsoy S, Basturk M, Esel E. Cerebellar syndrome in a patient with pneumonia under lithium treatment: a case report. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006;30(8):1532-1534. [CrossRef]
83. Niethammer M, Ford B. Permanent lithium-induced cerebellar toxicity: three cases and review of literature. *Mov Disord*. 2007;22(4):570-573. [CrossRef]
84. Tharoor H, Deora S, Chauhan A, Narasimha Sharma PSV. Lithium-neuroleptic combination leading to permanent neurological sequelae? *Ger J Psychiatry*. 2007;10(1):18-20.
85. Fischera M, Anneken K, Evers S, Kloska S, Husstedt IW. Cerebellar atrophy after long-term treatment with low-dose lithium. *Pharmacopsychiatry*. 2009;42(3):125-126. [CrossRef]
86. Ikeda Y, Kameyama M, Narita K, et al. Total and regional brain volume reductions due to the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT): a voxel-based morphometric study. *Prog Neuropsychopharmacol Biol Psychiatry*. 2010;34(1):244-246. [CrossRef]
87. Porto FHG, Leite MAA, Fontenelle LF, Marrocos RP, Szczerback NF, de Freitas MRG. The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT): one-year follow-up of a single case. *J Neurol Sci*. 2009;277(1-2):172-173. [CrossRef]
88. Kohen I. Permanent lithium-induced cerebellar toxicity in an elderly patient: case report and review of the literature. *Clin Geriatr*. 2011;19(6):26-27.
89. Feldman WB, Besterman AD, Yu JJP, Devido JJ, Bourgeois JA. Persistent perceptual disturbances after lithium toxicity: a case report and discussion. *Psychosomatics*. 2015;56(3):306-310. [CrossRef]
90. Banwari G, Chaudhary P, Panchmatia A, Patel N. Persistent cerebellar dysfunction following acute lithium toxicity: a report of two cases. *Indian J Pharmacol*. 2016;48(3):331-333. [CrossRef]
91. Huang SS. Prolonged dyskinesia following lithium intoxication in an elderly patient with bipolar I disorder. *Kaohsiung J Med Sci*. 2016;32(5):278-279. [CrossRef]
92. Cervello S, Cancel A, Boutet C, et al. Atypical permanent neurological sequelae after an acute intoxication with lithium and aripiprazole. *J Affect Disord*. 2017;214:97-99. [CrossRef]
93. Rossi FH, Rossi EM, Hoffmann M, et al. Permanent cerebellar degeneration after acute hyperthermia with non-toxic lithium levels: a case report and review of literature. *Cerebellum*. 2017;16(5-6):973-978. [CrossRef]
94. Medda P, Soggi C, Toni C, et al. Neurological deficits after lithium intoxication in a bipolar woman with catatonia treated with ECT. *J Clin Psychopharmacol*. 2018;38(4):405-407. [CrossRef]
95. Fountoulakis KN, Tegos T, Kimiskidis V. Lithium monotherapy-induced tardive dyskinesia. *J Affect Disord*. 2019;244:78-79. [CrossRef]
96. Cuigniez M, Audenaert K, Santens P, Heylens G. SILENT: the syndrome of irreversible lithium-effectuated neurotoxicity: a case report with two years follow-up. *Clin Neurol Neurosurg*. 2020;195:106057. [CrossRef]
97. Seña MM, Sarapuddin G, Sanieel E. A case report on an atypical presentation of the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT) in a war veteran with bipolar disorder and PTSD. *Case Rep Psychiatry*. 2020;2020:5369297. [CrossRef]
98. Rhee SY, Kim HS. Subcortical structure disruption in diffusion tensor tractography of the patient with the syndrome of irreversible lithium-effectuated neurotoxicity combined with neuroleptic malignant syndrome: a case report. *Clin Neuropharmacol*. 2021;44(2):62-67. [CrossRef]
99. Jha A, Pai NM, Ganjekar S, Desai G, Chaturvedi SK. Resurrecting the discussion on neurotoxicity of lithium at therapeutic levels. *Int Clin Psychopharmacol*. 2021;36(2):106-108. [CrossRef]
100. Akkus M. A case of dose-dependent lithium-induced tardive dyskinesia. *J Affect Disord*. 2022;299:205-206. [CrossRef]
101. Fenner RM, Bookbinder S, Kratzer J, McNeal A. Lithium toxicity with lasting mental status impairment. *Cureus*. 2022;14(8):e28076. [CrossRef]
102. Farouji A, Battah A, Ahmad AS, Farouji I, Miller R. A unique case of the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT) presenting with multiple neurological sequelae. *Cureus*. 2023;15(4):e38102. [CrossRef]
103. Netto I, Phutane VH. Reversible lithium neurotoxicity: review of the literature. *Prim Care Companion CNS Disord*. 2012;14(1). [CrossRef]
104. MacLeod-Glover N, Chuang R. Chronic lithium toxicity: considerations and systems analysis. *Can Fam Physician*. 2020;66(4):258-261.
105. Tondo L, Alda M, Bauer M, et al. Clinical use of lithium salts: guide for users and prescribers. *Int J Bipolar Disord*. 2019;7(1):16. [CrossRef]
106. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord*. 2018;20(2):97-170. [CrossRef]
107. Small JG, Klapper MH, Malloy FW, Steadman TM. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. *J Clin Psychopharmacol*. 2003;23(3):223-228. [CrossRef]
108. Sajatovic M, Strejilevich SA, Gildengers AG, et al. A report on older-age bipolar disorder from the international society for bipolar disorders task force. *Bipolar Disord*. 2015;17(7):689-704. [CrossRef]
109. Valerio MP, Lomastro J, Igoa A, Martino DJ. Correlates of neurological soft signs in bipolar disorder. *Eur Arch Psychiatry Clin Neurosci*. 2023;273(5):1183-1190. [CrossRef]
110. Chrobak AA, Soltys Z, Dudek D, Siwek M. Neurological and cerebellar soft signs in bipolar disorder: the role of staging, type and history of psychotic symptoms. *Prog Neuropsychopharmacol Biol Psychiatry*. 2023;121:110673. [CrossRef]
111. Bora E, Akgül Ö, Ceylan D, Özerdem A. Neurological soft signs in bipolar disorder in comparison to healthy controls and schizophrenia: a meta-analysis. *Eur Neuropsychopharmacol*. 2018;28(11):1185-1193. [CrossRef]
112. Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. *Lancet*. 2015;386(9992):461-468. [CrossRef]
113. Aiff H, Attman PO, Aurell M, et al. Effects of 10 to 30 years of lithium treatment on kidney function. *J Psychopharmacol*. 2015;29(5):608-614. [CrossRef]
114. Noronha IL, Santa-Catharina GP, Andrade L, Coelho VA, Jacob-Filho W, Elias RM. Glomerular filtration in the aging population. *Front Med (Lausanne)*. 2022;9:769329. [CrossRef]
115. Shulman KI, Almeida OP, Herrmann N, et al. Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: an ISBD task force report. *Bipolar Disord*. 2019;21(2):117-123. [CrossRef]
116. Buckley NA, Cheng S, Isoardi K, et al. Haemodialysis for lithium poisoning: translating EXTRIP recommendations into practical guidelines. *Br J Clin Pharmacol*. 2020;86(5):999-1006. [CrossRef]
117. National Collaborating Centre for Mental Health (UK). *Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care*. The British Psychological Society and The Royal College of Psychiatrists; 2014.
118. Liu YH, Tsai KF, Hsu PC, et al. Hemodialysis treatment for patients with lithium poisoning. *Int J Environ Res Public Health*. 2022;19(16):10044. [CrossRef]
119. Tesio L. Reply to Adityanjee. *J Neurol Neurosurg Psychiatry*. 1987;50:1246-1247.